Epoprostenol

Epoprostenol

SCHEMBL41344

CCCCC[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)[O-])O[C@H]2C[C@H]1O.[Na+]

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGIR

The experimentally established mechanism targets of Epoprostenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGIR known ✓ P43119 4/20 0.46
ALDH1A1 P00352 5/20 0.82
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
PPARG P37231 1/20 0.58
PPARD Q03181 1/20 0.58
PPARA Q07869 1/20 0.58
PTGFR P43088 5/20 0.46
PTGER4 P35408 4/20 0.46
TBXA2R P21731 4/20 0.46
PTGER2 P43116 3/20 0.46
TSHR P16473 3/20 0.46
PTGER1 P34995 2/20 0.46
PTGER3 P43115 2/20 0.46
HPGD P15428 2/20 0.46
MAPK1 P28482 2/20 0.46
NR1I2 O75469 1/20 0.46
ESR1 P03372 1/20 0.46
PGR P06401 1/20 0.46
OPRK1 P41145 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Epoprostenol SCHEMBL4299219 1.00 ALDH1A1 (0.82) ALDH1A1MEN1KMT2APPARGPPARD
Epoprostenol SCHEMBL128619 1.00 ALDH1A1 (0.82) ALDH1A1MEN1KMT2APPARGPPARD
Epoprostenol SCHEMBL29121502 1.00 ALDH1A1 (0.82) ALDH1A1MEN1KMT2APPARGPPARD
Epoprostenol SCHEMBL5452422 0.96 ALDH1A1 (0.90) ALDH1A1MEN1KMT2APPARGPPARD
Epoprostenol SCHEMBL24612535 0.90 ALDH1A1 (1.00) ALDH1A1MEN1KMT2APPARGPPARD
Epoprostenol SCHEMBL705594 0.90 ALDH1A1 (1.00) ALDH1A1MEN1KMT2APPARGPPARD
Epoprostenol SCHEMBL16783375 0.90 ALDH1A1 (1.00) ALDH1A1MEN1KMT2APPARGPPARD
Epoprostenol SCHEMBL24033081 0.90 ALDH1A1 (1.00) ALDH1A1MEN1KMT2APPARGPPARD
Epoprostenol SCHEMBL21283002 0.90 ALDH1A1 (1.00) ALDH1A1MEN1KMT2APPARGPPARD
Epoprostenol SCHEMBL22607961 0.90 ALDH1A1 (1.00) ALDH1A1MEN1KMT2APPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2648 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250367179-A1 COMPOSITION AND METHODS FOR TREATING HERITABLE PULMONARY ARTERY HYPERTENSION ASSOCIATED WITH NONSENSE MUTATIONS LUNDQUIST INST FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL CENTER (US) 2025-12-04 US claimed
US-20250161220-A1 LYMPHATIC DELIVERY OF NANOPARTICLES TO TREAT NEURODEGENERATIVE, NEUROLOGICAL, AND EYE CONDITIONS THE CLEVELAND CLINIC FOUNDATION 2025-05-22 US claimed
EP-4479029-A2 LYMPHATIC DELIVERY OF NANOPARTICLES TO TREAT NEURODEGENERATIVE, NEUROLOGICAL, AND EYE CONDITIONS The Cleveland Clinic Foundation (US) 2024-12-25 EP claimed
US-20240282425-A1 AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS LOW GORDON KEITH (US) 2024-08-22 US claimed
US-20230310478-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION AND CANCER ZHAO, Youyang 2023-10-05 US claimed
WO-2023159114-A2 LYMPHATIC DELIVERY OF NANOPARTICLES TO TREAT NEURODEGENERATIVE, NEUROLOGICAL, AND EYE CONDITIONS THE CLEVELAND CLINIC FOUNDATION (US) 2023-08-24 WO claimed
US-11714094-B2 Composition comprising prostacyclin andor analogues thereof for treatment of acute critically ill patients ENDOTHEL PHARMA APS (DK) 2023-08-01 US claimed
US-20230000850-A1 COMPOSITION AND METHODS FOR TREATING HERITABLE PULMONARY ARTERY HYPERTENSION ASSOCIATED WITH NONSENSE MUTATIONS LUNDQUIST INST FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL CENTER (US) 2023-01-05 US claimed
EP-4069826-A1 EXTRACELLULAR VESICLES AND THEIR USES United Therapeutics Corporation (US) 2022-10-12 EP claimed
CN-109153660-B Method for preparing epoprostenol sodium with enhanced stability 奇诺因药物和化学工厂私人有限公司 2022-10-11 CN claimed
WO-2002058734-A2 COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS SCHERING CORPORATION (US) 2002-08-01 WO claimed
US-20020049155-A1 Cobalamin compounds useful as cardiovascular agents and as imaging agents HOGENKAMP HENRICUS P C (US) 2002-04-25 US claimed
WO-2002026318-A1 METHOD AND SYSTEM FOR NERVE STIMULATION AND CARDIAC SENSING PRIOR TO AND DURING A MEDICAL PROCEDURE MEDTRONIC, INC. (US) 2002-04-04 WO claimed
WO-2001092283-A2 COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2001-12-06 WO claimed
US-4430340-A HEXADECYLTRIMETHYLAMMONIUM CHLORIDE, WATER, PROSTACYCLIN SODIUM SALT, DRUGS THE UPJOHN COMPANY (US) 1984-02-07 US claimed
EP-0005768-B1 PHARMACEUTICAL FORMULATIONS CONTAINING PROSTAGLANDIN COMPOUNDS AND METHOD FOR THEIR PREPARATION THE WELLCOME FOUNDATION LIMITED (GB) 1983-08-10 EP claimed
EP-0007245-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING PROSTACYCLIN OR A PROSTACYCLIN ANALOGUE CONTAINING AN ENOL ETHER GROUP THE UPJOHN COMPANY (US) 1982-12-08 EP claimed
US-4335139-A PROSTAGLANDINS BURROUGHS WELLCOME CO. (US) 1982-06-15 US claimed
EP-0007245-A1 Pharmaceutical compositions comprising prostacyclin or a prostacyclin analogue containing an enol ether group THE UPJOHN COMPANY (US) 1980-01-23 EP claimed
EP-0005768-A1 Pharmaceutical formulations containing prostaglandin compounds and method for their preparation THE WELLCOME FOUNDATION LIMITED (GB) 1979-12-12 EP claimed